

Andrew M Hughes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6554149/publications.pdf>

Version: 2024-02-01

27
papers

3,077
citations

361413
20
h-index

552781
26
g-index

27
all docs

27
docs citations

27
times ranked

4596
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Technology clinical trials: Turning innovation into patient benefit. Digital Health, 2021, 7, 205520762110121. | 1.8 | 2 |
| 2 | Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials. Cancers, 2021, 13, 2443. | 3.7 | 4 |
| 3 | Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nature Medicine, 2017, 23, 114-119. | 30.7 | 260 |
| 4 | Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU International, 2014, 114, E70-E73. | 2.5 | 30 |
| 5 | Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Research, 2014, 24, 40-46. | 1.2 | 67 |
| 6 | Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System. Journal of Molecular Diagnostics, 2014, 16, 343-349. | 2.8 | 44 |
| 7 | Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. Journal of Investigative Dermatology, 2013, 133, 1582-1590. | 0.7 | 122 |
| 8 | Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. Journal of Thoracic Oncology, 2012, 7, 306-315. | 1.1 | 411 |
| 9 | A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients. Clinical Drug Investigation, 2012, 32, 179-187. | 2.2 | 25 |
| 10 | Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 1556-1563. | 1.6 | 788 |
| 11 | Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer. American Journal of Pathology, 2011, 178, 989-996. | 3.8 | 386 |
| 12 | Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Research and Treatment, 2010, 120, 461-467. | 2.5 | 191 |
| 13 | Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome. Proteomics - Clinical Applications, 2009, 3, 394-407. | 1.6 | 15 |
| 14 | Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. American Journal of Pathology, 2009, 175, 808-816. | 3.8 | 223 |
| 15 | Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer. Annals of the New York Academy of Sciences, 2008, 1137, 98-107. | 3.8 | 90 |
| 16 | Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Molecular Cancer Therapeutics, 2008, 7, 455-463. | 4.1 | 56 |
| 17 | Multiplexed Assays for Detection of Mutations in PIK3CA. Clinical Chemistry, 2008, 54, 757-760. | 3.2 | 72 |
| 18 | Serum biomarkers of apoptosis. European Journal of Cancer, Supplement, 2007, 5, 115-127. | 2.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer. Biomarker Insights, 2007, 2, 117727190700200. | 2.5 | 26 |
| 20 | A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers. Cancer Chemotherapy and Pharmacology, 2007, 60, 391-398. | 2.3 | 23 |
| 21 | A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers. Cancer Chemotherapy and Pharmacology, 2007, 60, 479-488. | 2.3 | 22 |
| 22 | Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry. Analytical Biochemistry, 2006, 352, 33-40. | 2.4 | 8 |
| 23 | Staged Risk Management of Candidate Drug Efficacy. Pharmaceutical Medicine, 2005, 19, 227-232. | 0.4 | 2 |
| 24 | Effect of oral linezolid on the pressor response to intravenous tyramine. British Journal of Clinical Pharmacology, 2004, 58, 470-475. | 2.4 | 24 |
| 25 | The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology, 2003, 124, 18-25. | 1.3 | 128 |
| 26 | Novel approaches in oncology at AstraZeneca. European Journal of Cancer, Supplement, 2003, 1, 3-8. | 2.2 | 7 |
| 27 | Assessment of the reproducibility of intradermal administration of capsaicin as a model for inducing human pain. Pain, 2002, 99, 323-331. | 4.2 | 51 |